Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Tirzepatide decreased numerous measures of appetite or the drive to eat ... two important hormone pathways that help control hunger. As of today, there are no medications on the market that purely ...

Roughly one in three preteens and teens ages 12 to 17 in the United States had prediabetes in 2023, according to new data ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body weight, food intake and many measures of appetite more than placebo and ...

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...

Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Preclinical study shows oral PL7737 agonist outperforms tirzepatide alone in rodent models, supporting Palatin’s plans for ...

More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor ...

Learn how Mounjaro (tirzepatide) may reverse pre-diabetes in young adults in India, its benefits, and why early action is key.

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping treatment.